This study provides an analytical framework, drawing on production function theory, to identify and quantify the determinants of relative effectiveness and sources of variation in the relative effectiveness of treatments between populations and healthcare systems. Relative effectiveness is a key…
This study provides an analytical framework, drawing on production function theory, to identify and quantify the determinants of relative effectiveness and sources of variation in the relative effectiveness of treatments between populations and healthcare systems.
Relative effectiveness is a key topic within health policy. In Europe, this is due to the need for early information to guide reimbursement and funding decisions about new medical technologies. However, the reasons why evidence on effectiveness (does it work?) and efficacy (can it work?) might differ across health systems are poorly understood.
Two papers have been published in the International Journal of Technology Assessment in Health Care in which OHE’s Adrian Towse, Jorge Mestre-Ferrandiz and Nancy Devlin have collaborated with external researchers to:
The first paper finds that better evidence on factors driving relative effectiveness could:
The authors conclude there is a strong case for exploring the use of a health production function approach to better understand the impact of new medicines and devices for improvements in health outcomes. Moreover, the health production function approach is complementary to traditional experimental and observational studies, focusing on identifying, collecting, and analysing data at the national level, enabling comparisons to take place.
The second paper focuses on breast cancer. In order to highlight potential cross-country differences in the relative effectiveness of a new drug we reviewed studies investigating reasons for differences in health outcomes in breast cancer. We also reviewed relevant national clinical guidelines and health technology assessment (HTA) reports to understand similarities and differences in the management of breast cancer between countries. We show how our analytical framework can help to understand the factors that might drive differences in relative effectiveness across different settings.
The review included thirteen international studies and thirty country-specific studies. Cross-country differences in population age structure, deprivation, and educational attainment were consistently associated with variation in outcomes. Screening intensity appeared to drive differences in survival, although the impact on mortality was unclear.
Studies that show differences in relative effectiveness between countries, or that identify factors suggesting these exist, provide one way to identify how health system performance can be improved.
Finally, we consider the implications for data sharing across health care systems. For example,
For more information please contact Jorge Mestre-Ferrandiz at OHE.
An error has occurred, please try again later.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!